Royalty Pharma buys partial royalty interest on Prevymis from AiCuris Anti-infective Cures GmbH
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.
Pharmaceuticals, Biotechnology and Life Sciences
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.
Packaging Technology Group, Inc., (PTG), a leading provider of thermal packaging solutions for the biopharmaceutical and life sciences sector, has opened a new location in Louisville, Kentucky.
LONDON–(BUSINESS WIRE)–#CompetitiveIntelligence–Infiniti Research is the world’s leading independent provider of strategic market intelligence solutions. Our market intelligence services are designed…
TORONTO–(BUSINESS WIRE)–#FSDDF—FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private…
RECARBRIO is Indicated to Treat Multiple Infections Caused by Susceptible Gram-Negative Bacteria in Adults KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…
New fund will be deployed to create breakthrough biotech startups Michael Gladstone is promoted to partner CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atlas Venture,…
The first weed control traits in rice and flax bred by precision gene editing to be advanced in commercial development…
TORONTO–(BUSINESS WIRE)–#FSDDF–FSD Pharma Inc. (NASDAQ: HUGE) (“FSD Pharma” or the “Company”), today announced it has entered into definitive agreements with…
FDA published on Wednesday a new batch of product-specific guidances (PSGs), providing recommendations for developing generic drugs and generating the evidence needed to support Abbreviated New Drug Application (ANDA) approval.
The Larvol Group on Monday announced the launch of Veri, their new decision support and competitive intelligence tool during the 2020 ASCO Annual Meeting.